期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 26, 期 4, 页码 833-844出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2017.12.047
关键词
Efflux pumps; Chemosensitizers; Macrophages; Efflux pump inhibitors; M. tuberculosis; Ethidium bromide
资金
- University of Cape Town
- South African Medical Research Council (SAMRC)
- South African Research Chairs Initiative of the Department of Science and Technology
- DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University
Novel reversed isoniazid (RINH) agents were synthesized by covalently linking isoniazid with various efflux pump inhibitor (EPI) cores and their structural motifs. These RINH agents were then evaluated for anti-mycobacterial activity against sensitive, isoniazid mono-resistant and MDR clinical isolates of M. tuberculosis and a selected number of compounds were also tested ex vivo for intracellular activity as well as in the ethidium bromide (EB) assay for efflux pump inhibition efficacy. The potency of some compounds against various strains of M. tuberculosis (4a-c, 7 and 8; H37Rv-MIC99 <= 1.25 mu M, R5401-MIC99 <= 2.5 mu M, X_61-MIC99 <= 5 mu M) demonstrated the potential of the reversed anti-TB agent strategy towards the development of novel anti-mycobacterial agents to address the rapidly growing issue of resistance. Further, macrophage activity with >90% inhibition by 1a-c and 3b (MIC90 <= 13.42 mu M) and inhibition of EB efflux demonstrated by these compounds are encouraging. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据